{"id":745074,"date":"2015-11-16T08:30:00","date_gmt":"2015-11-16T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/"},"modified":"2025-11-07T01:24:47","modified_gmt":"2025-11-07T06:24:47","slug":"merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/","title":{"rendered":"Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Advances to Part B of C-CREST Phase 2 Clinical        Development Program     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of results from the initial phase (Part<br \/>\n      A) of the company\u2019s <i>C-CREST<\/i> <i>1<\/i> and<i> 2<\/i> Phase 2<br \/>\n      clinical development program evaluating two investigational all-oral,<br \/>\n      triple-combination treatment regimens \u2013 a regimen of grazoprevir<sup>1<\/sup>,<br \/>\n      MK-3682<sup>2<\/sup> and<sup> <\/sup>elbasvir<sup>3<\/sup>; and a regimen<br \/>\n      of grazoprevir, MK-3682 and MK-8408<sup>4<\/sup> \u2013 in treatment-na\u00efve<br \/>\n      patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3<br \/>\n      infection. These data will be presented today during a late-breaking<br \/>\n      abstract session at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aasld.org%2Fevents-professional-development%2Fliver-meeting&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=The+Liver+Meeting%C2%AE&amp;index=1&amp;md5=daf1ed0a92db91b3d68ae933ecae8b53\" rel=\"nofollow\">The<br \/>\n      Liver Meeting<sup>\u00ae<\/sup><\/a> (Abstract #LB-15). Based on the results of<br \/>\n      this initial trial, Merck has initiated further study of grazoprevir<br \/>\n      (100mg), MK-3682 (450mg) and MK-8408 (60mg) in the second phase (Part B)<br \/>\n      of the <i>C-CREST<\/i> Phase 2 clinical development program.\n    <\/p>\n<p>\n      \u201cMerck\u2019s chronic hepatitis C development program continues to focus on<br \/>\n      the goal of advancing a short-duration treatment regimen that offers<br \/>\n      high virologic cure rates across all viral genotypes,\u201d said Dr. Roy<br \/>\n      Baynes, senior vice president and head of global clinical development,<br \/>\n      Merck Research Laboratories. \u201cThe strong results observed in this study<br \/>\n      support the further investigation of the novel triple-combination<br \/>\n      regimen of grazoprevir, MK-3682 and MK-8408 in patients with chronic<br \/>\n      hepatitis C.\u201d\n    <\/p>\n<p>\n      In these randomized, open-label clinical trials, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02332707&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=C-CREST+1&amp;index=2&amp;md5=d30c2f1e1b6e7724ed142bd928b2c625\" rel=\"nofollow\"><i>C-CREST<br \/>\n      1<\/i><\/a> evaluated treatment-naive, non-cirrhotic patients with chronic<br \/>\n      HCV GT1 or 2 infection and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02332720&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=C-CREST+2&amp;index=3&amp;md5=2e8b81ddafa56aaf022dfb0fd88d54b5\" rel=\"nofollow\"><i>C-CREST<br \/>\n      2<\/i><\/a> evaluated treatment-naive, non-cirrhotic patients with chronic<br \/>\n      HCV GT3 infection. The primary efficacy endpoint was sustained virologic<br \/>\n      response 12 weeks after the completion of treatment (SVR12, or virologic<br \/>\n      cure). All 240 enrolled patients completed eight weeks of treatment and<br \/>\n      reached follow-up 12 weeks after end of treatment. Treatment with<br \/>\n      grazoprevir (100mg), MK-3682 (450mg) and MK-8408 (60mg), without<br \/>\n      ribavirin (RBV), for eight weeks resulted in virologic cure rates of<br \/>\n      greater than 90 percent across chronic HCV patients with GT1, 2 or 3<br \/>\n      infection, which supported the decision to advance this regimen into<br \/>\n      Part B of the <i>C-CREST<\/i> Phase 2 clinical trial program.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td colspan=\"11\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">\n<p class=\"bwcellpmargin\">\n            <b>Summary of SVR12 Findings Following 8 Weeks of Treatment*: <i>C-CREST<br \/>\n            1 <\/i>and<i> 2<\/i> Part A<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\" colspan=\"11\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>Population<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>N<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Grazoprevir<\/b><br \/><b>+ Elbasvir<\/b><br \/><b>+ MK-3682<\/b><br \/><b><br \/>\n            300mg<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Grazoprevir<\/b><br \/><b>+ Elbasvir<\/b><br \/><b>+ MK-3682<\/b><br \/><b>450mg<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Grazoprevir<\/b><br \/><b>+ MK-8408<\/b><br \/><b>+ MK-3682<\/b><br \/><b><br \/>\n            300mg<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Grazoprevir<\/b><br \/><b>+ MK-8408<\/b><br \/><b>+ MK-3682<\/b><br \/><b><br \/>\n            450mg<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          GT1\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          93\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (23\/23)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (23\/23)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (24\/24)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          91% (21\/23)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          GT2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          61\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          69% (11\/16)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          60% (9\/15)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          71% (10\/14)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          94% (15\/16)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          GT3\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          86\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          90% (19\/21)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          86% (19\/22)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          95% (20\/21)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          91% (20\/22)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"11\">\n<p class=\"bwcellpmargin\">\n            *Treatment-naive, non-cirrhotic patients\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"11\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The most commonly reported adverse events across all regimens (greater<br \/>\n      than 10% incidence) were headache (23%), fatigue (20%) and nausea (13%).<br \/>\n      There were no drug-related serious adverse events and no<br \/>\n      discontinuations due to adverse events.\n    <\/p>\n<p>\n      <b>About the <i>C-CREST<\/i> Program<\/b>\n    <\/p>\n<p>\n      The <i>C-CREST<\/i> Phase 2 clinical development program is designed to<br \/>\n      evaluate the safety and efficacy of Merck\u2019s triple-combination treatment<br \/>\n      regimens in patients with chronic HCV GT1, 2 or 3 infection. The<br \/>\n      investigational medicines studied in the initial phase (Part A) of the <i>C-CREST<\/i><br \/>\n      program included:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Grazoprevir (MK-5172), an HCV NS3\/4A protease inhibitor\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        MK-3682, an oral prodrug HCV nucleotide analogue NS5B polymerase<br \/>\n        inhibitor\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Elbasvir (MK-8742), an HCV NS5A replication complex inhibitor\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        MK-8408, an HCV NS5A replication complex inhibitor\n      <\/li>\n<\/ul>\n<p>\n      Based on the results from the initial phase (Part A) in treatment-naive,<br \/>\n      non-cirrhotic chronic HCV patients, Merck has initiated further study of<br \/>\n      grazoprevir, MK-3682 and MK-8408 in the second phase (Part B) of the <i>C-CREST<\/i><br \/>\n      Phase 2 program. Part B will evaluate the safety and efficacy of this<br \/>\n      regimen with or without RBV in chronic HCV patients with GT1, 2 or 3<br \/>\n      infection for different treatment durations. The various study arms will<br \/>\n      include treatment-naive patients with or without compensated cirrhosis<br \/>\n      or with HIV\/HCV co-infection, as well as treatment-experienced patients<br \/>\n      (previously treated with pegylated interferon\/RBV) with GT3 infection.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For nearly 30 years, Merck has been at the forefront of the response to<br \/>\n      the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to deliver innovative<br \/>\n      healthcare solutions that support people living with HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=94d5dcff1c149912f5ab44af2d80e373\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=0c03b6d380fc308f40e59a3407c2d9f7\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=69fb7a3ce107fff039362a0a03c07f50\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=2f0934cbcdbb076aa81dcbad2489fa40\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=1dd8d60c4a350e16858d23e0640f2072\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51224722&amp;newsitemid=20151116005459&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=01343bf3f75ff842cb82e43db963b21b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">\n            ____________________\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          <sup>1<\/sup> Grazoprevir is an HCV NS3\/4A protease inhibitor (100mg).\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          <sup>2<\/sup> MK-3682 is an oral prodrug HCV nucleotide analogue NS5B<br \/>\n          polymerase inhibitor (300mg or 450mg).\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          <sup>3<\/sup> Elbasvir is an HCV NS5A replication complex inhibitor<br \/>\n          (50mg).\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          <sup>4<\/sup> MK-8408 is an HCV NS5A replication complex inhibitor<br \/>\n          (60mg).\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151116005459r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>Sarra Herzog,        201-669-6570<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the company\u2019s C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens \u2013 a regimen of grazoprevir 1 , MK-3682 2 and elbasvir 3 ; and a regimen of grazoprevir, MK-3682 and MK-8408 4 \u2013 in treatment-na\u00efve patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. These data will be presented today during a late-breaking abstract session at The Liver Meeting\u00ae (Abstract #LB-15). Based on the results of this initial trial, Merck has initiated further study of grazoprevir (100mg), MK-3682 (450mg) and MK-8408 (60mg) in the second phase (Part B) of the C-CREST Phase 2 clinical development program. \u201cMerck\u2019s chronic hepatitis C development program continues to focus on the goal of advancing a short-duration treatment regimen that offers high virologic<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745074","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the company\u2019s C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens \u2013 a regimen of grazoprevir 1 , MK-3682 2 and elbasvir 3 ; and a regimen of grazoprevir, MK-3682 and MK-8408 4 \u2013 in treatment-na\u00efve patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. These data will be presented today during a late-breaking abstract session at The Liver Meeting\u00ae (Abstract #LB-15). Based on the results of this initial trial, Merck has initiated further study of grazoprevir (100mg), MK-3682 (450mg) and MK-8408 (60mg) in the second phase (Part B) of the C-CREST Phase 2 clinical development program. \u201cMerck\u2019s chronic hepatitis C development program continues to focus on the goal of advancing a short-duration treatment regimen that offers high virologic\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\\\/\",\"name\":\"Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-11-16T08:30:00+00:00\",\"dateModified\":\"2025-11-07T06:24:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the company\u2019s C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens \u2013 a regimen of grazoprevir 1 , MK-3682 2 and elbasvir 3 ; and a regimen of grazoprevir, MK-3682 and MK-8408 4 \u2013 in treatment-na\u00efve patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. These data will be presented today during a late-breaking abstract session at The Liver Meeting\u00ae (Abstract #LB-15). Based on the results of this initial trial, Merck has initiated further study of grazoprevir (100mg), MK-3682 (450mg) and MK-8408 (60mg) in the second phase (Part B) of the C-CREST Phase 2 clinical development program. \u201cMerck\u2019s chronic hepatitis C development program continues to focus on the goal of advancing a short-duration treatment regimen that offers high virologic","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:47+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/","name":"Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-11-16T08:30:00+00:00","dateModified":"2025-11-07T06:24:47+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-results-from-two-phase-2-studies-of-investigational-triple-combination-chronic-hepatitis-c-therapy-at-the-liver-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"23ab2abd-e4e7-4710-a340-456587ba231b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Presentation-of-Results-from-Two-Phase-2-Studies-of-Investigational-Triple-Combination-Chronic-Hepatitis-C-Therapy-at-78M2C.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745074\/revisions"}],"predecessor-version":[{"id":3674570,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745074\/revisions\/3674570"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745074"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}